



NDA 202276/S-017

**SUPPLEMENT APPROVAL**

Metuchan Pharmaceuticals, LLC c/o Mist Pharmaceuticals  
Attention: Keith S. Rotenberg, Ph.D.  
11 Commerce Drive  
First Floor  
Cranford, NJ 07016

Dear Dr. Rotenberg:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 22, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for STENDRA® (avanafil) tablets.

We also refer to our safety labeling change notification letter dated, May 5, 2017, notifying you, under Section 505(o)(4) of the FDCA, of new safety information, regarding the risk of non-arteritic anterior ischemic optic neuropathy (NAION), that you had incorporated into labeling and submitted as a prior approval supplement. On August 16, 2017, a supplement approval letter was sent approving the labeling text. Upon review of the agreed-upon labeling text, you had discovered an error in the prescribing information (PI), which consisted of figure 3 being a duplicate of figure 4.

Therefore, this “Changes Being Effected” supplemental new drug application provides for revisions to the labeling for Stendra, which include an update to figure 3 of the PI.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for

the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Meredith Hillig, MS, Safety Regulatory Project Manager, at (301) 796-1218.

Sincerely,

*{See appended electronic signature page}*

Christine P. Nguyen, M.D.  
Acting Director  
Division of Bone, Reproductive and Urologic Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

CHRISTINE P NGUYEN  
10/10/2017